Gain Therapeutics, Inc. (GANX) Form 8-K — Oct 28, 2026
Gain Therapeutics appointed Jeanette Weidner as Vice President, Finance effective October 28, 2026, and she will also serve as the company's principal financial officer and principal accounting officer. Ms. Weidner, 44, brings 18 years of accounting and finance experience, including VP Finance at OncoC4 and most recently a financial consulting role at Senseonics Holdings. She receives a $275,000 base salary, a 35% target bonus, and an option for 130,000 shares vesting over four years.
Key figures
- Vesting
- 4 years, 25% cliff at 1 year
- Severance
- 6 months salary (12 months plus accelerated vesting on Change of Control termination)
- Base Salary
- 275000
- Option Shares
- 130000
- Target Bonus Percent
- 35%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.